---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086535"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:40:14.209893+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix Q2 net loss $(43.8)M; AXPAXLI SOL-R accepted as pivotal trial

## Summary
- Net loss of $(43.8)M ($(0.26)/share) vs $(20.7)M ($(0.26)/share) in Q2 2023; revenue $16.4M (+8.3% YoY).
- Cash $459.7M as of June 30, 2024; expected to fund operations into 2028.
- FDA confirmed SOL-R repeat dosing study (Phase 3 wet AMD) is appropriate as second registrational trial; ~825 subjects to be randomized.
- SOL-1 enrollment accelerating: 151 subjects enrolled as of June 7, 2024, 60 active sites.
- HELIOS Phase 1 NPDR data showed DRSS improvement; no intraocular inflammation; presented at ASRS.

## SEC filing metadata
- accession: 0001104659-24-086535
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465924086535/0001104659-24-086535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465924086535/tm2420962d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086535
- JSON: https://secwatch.observer/filing/0001104659-24-086535.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086535.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.